Similarly, due to their high expression in immune cells, inhibitors of p110δ and p110γ (or targeting both isoforms) have been tested in many haematological malignancies, with a selective p110δ inhibitor (Idelalisib) approved for use in chronic lymphocytic leukemia and follicular B-cell non-Hodgkin lymphoma [125]. The gene discussed is PIK3CD; the disease is B-cell chronic lymphocytic leukemia.